Close Menu

SAN FRANCISCO – Roche and Illumina said at the JP Morgan Healthcare Conference here on Monday that they have formed a partnership focused on driving the adoption of next-generation sequencing assays for oncology.

Under the 15-year, non-exclusive agreement with Roche, Illumina will grant Roche rights to develop and distribute in vitro diagnostic tests on Illumina's NextSeq 550Dx System, as well as on its future portfolio of Dx-branded sequencing systems, including the forthcoming NovaSeqDx.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.